- Home
- SYNX vs APM Comparison
SYNX vs APM Comparison
Compare SYNX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYNX | APM |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.0M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SYNX | APM |
|---|---|---|
| Price | $1.23 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 21.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.65 |
| 52 Week High | $4.55 | $4.47 |
Technical Indicators
Market Signals| Indicator | SYNX | APM |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 44.46 |
| Support Level | $0.90 | $0.74 |
| Resistance Level | $1.31 | $1.11 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 31.25 | 42.15 |
Price Performance
Historical ComparisonAbout SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.